Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by American College of Cardiology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American College of Cardiology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Revisiting the SUMMIT Trial | JACC Deep Dive

5:55
 
Share
 

Manage episode 480899476 series 180467
Content provided by American College of Cardiology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American College of Cardiology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

This JACC Deep Dive in our May 13 issue highlights new findings from the SUMMIT CKD study, showing that terzepatide improves symptoms, function, and weight in patients with HFpEF and obesity—regardless of kidney function. The analysis also underscores the importance of using both creatinine and cystatin C to better assess kidney health. Reviewers praised the study’s methodological rigor and dual focus, while noting the need for larger, long-term trials to confirm renal outcomes.

  continue reading

3299 episodes

Artwork
iconShare
 
Manage episode 480899476 series 180467
Content provided by American College of Cardiology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American College of Cardiology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

This JACC Deep Dive in our May 13 issue highlights new findings from the SUMMIT CKD study, showing that terzepatide improves symptoms, function, and weight in patients with HFpEF and obesity—regardless of kidney function. The analysis also underscores the importance of using both creatinine and cystatin C to better assess kidney health. Reviewers praised the study’s methodological rigor and dual focus, while noting the need for larger, long-term trials to confirm renal outcomes.

  continue reading

3299 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play